These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3999398)

  • 1. [The effect of dilazep on red cell survival].
    Saito H; Saito A; Ogawa H
    Rinsho Ketsueki; 1985 Jan; 26(1):15-9. PubMed ID: 3999398
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effect of dilazep on circulating platelet aggregation in diabetics].
    Carleo R; Buda GR; Cerciello A; Dell'Aversano R; Monaco GP; Trovato C; Vigilante M
    Boll Soc Ital Biol Sper; 1983 Dec; 59(12):1832-7. PubMed ID: 6671042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes in platelet production of malondialdehyde in diabetics treated with dilazep].
    Carleo R; Buda GR; Cerciello A; Dell'Aversano R; Monaco GP; Trovato C; Vigilante M
    Boll Soc Ital Biol Sper; 1983 Dec; 59(12):1838-41. PubMed ID: 6671043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effects of dilazep dihydrochloride and vitamin E on P50 in patients with chronic obstructive pulmonary disease].
    Nishiura Y
    Nihon Kyobu Shikkan Gakkai Zasshi; 1985 May; 23(5):569-77. PubMed ID: 4057705
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of dilazep on shape change of human erythrocyte in blood stored over a period of 42 days.
    Fujisawa Y; Abiko Y
    Arzneimittelforschung; 1981; 31(9):1462-8. PubMed ID: 7197956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study on the effect of dilazep and dipyridamole on some platelet functions.
    Valori VM; Leone G; Traisci G; Bizzi B
    Arzneimittelforschung; 1982; 32(4):403-5. PubMed ID: 7201810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Red cell survival time in chronic renal failure.
    Rath RN; Das RK; Panda RK; Mahakur AC; Patnaik SR
    J Assoc Physicians India; 1979 Oct; 27(10):969-74. PubMed ID: 541318
    [No Abstract]   [Full Text] [Related]  

  • 8. Red cells life span, splenic sequestration and transfusion requirements in chronic renal failure treated by hemodialysis. Effects of bilateral nephrectomy.
    Laurent C; Wittek M; Vereerstraeten P; Toussaint C; Naets JP
    Clin Nephrol; 1974; 2(1):35-40. PubMed ID: 4823492
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effects of dilazep on the myocardium and smooth vascular muscle].
    Cargnoni A; Gargano M; Pelà G; Gallo P; Ferrari R; Raddino R
    Cardiologia; 1987 Oct; 32(10):1161-5. PubMed ID: 3690582
    [No Abstract]   [Full Text] [Related]  

  • 10. [Adenosine degradation in human erythrocytes in the presence of dilazep].
    Blum KU; Merkel R
    Arzneimittelforschung; 1976; 26(9):1638-42. PubMed ID: 1036691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracardiac electrophysiologic study of dilazep in man.
    Padeletti L; Michelucci A; Giomi A; Fradella GA; Monizzi D; Fantini F
    Int J Cardiol; 1984 Apr; 5(4):525-6. PubMed ID: 6724749
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of exogenous reduced glutathione on the survival of red blood cells in hemodialyzed patients.
    Usberti M; Lima G; Arisi M; Bufano G; D'Avanzo L; Gazzotti RM
    J Nephrol; 1997; 10(5):261-5. PubMed ID: 9364318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of myocardial reactive hyperemia and adenosine-induced coronary vasodilation by dilazep, a new adenosine potentiator.
    Saito D; Kusachi S; Nagashima H; Haraoka S
    Arzneimittelforschung; 1982; 32(9):1029-32. PubMed ID: 6890820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Behavior of heart rate and systolic arterial pressure during isometric exercise after administration of salbutamol, dilazep, indomethacin and a placebo].
    Arosio A; Sergi M; Grisetti GC; Mandelli V; Bosisio E
    Minerva Cardioangiol; 1982 Jun; 30(6):309-12. PubMed ID: 7133419
    [No Abstract]   [Full Text] [Related]  

  • 15. Human platelet aggregation tests in vitro. Effects of dilazep.
    Ponari O; Manotti C
    Arzneimittelforschung; 1981; 31(1):97-101. PubMed ID: 7194099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Agents to improve cerebrovascular circulation and cerebral metabolism--ATP and dilazep].
    Terashi A; Shimizu J
    Nihon Rinsho; 1985 Feb; 43(2):365-7. PubMed ID: 2987570
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of dilazep on reperfusion arrhythmias.
    Sugiyama S; Kondo T; Ajioka M; Hattori M; Nagai S; Ozawa T
    Arzneimittelforschung; 1985; 35(12):1802-4. PubMed ID: 4096732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polycentric and hemodynamic experimentation with a new coronary active drug: dilazep].
    Baldrighi V; Barbaresi F; Plancher AC; Portioli I
    Clin Ter; 1976 Aug; 78(4):303-62. PubMed ID: 795597
    [No Abstract]   [Full Text] [Related]  

  • 19. [Polygraphic and electrocardiographic study of a new coronary therapeutic agent: dilazep].
    Parenti B; Selvaggi R
    Clin Ter; 1980 Jan; 92(2):155-63. PubMed ID: 7389275
    [No Abstract]   [Full Text] [Related]  

  • 20. [Myocardial protection by dilazep in myocardial ischemia and reperfusion].
    Shida H; Kobayashi M; Chiba S
    Arzneimittelforschung; 1981; 31(11):1902-6. PubMed ID: 7198472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.